The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
HealthDay on MSN7d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionWEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression. The drug, SPRAVATO, is made by Johnson & Johnson and was first approved in 2019 for adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback